EUVIMEDEUVIMED entdecken
Klinische Studie

Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System

Cheng Yi Yuan, Yee W Kong, Tess Amoore, Katrin Brown, Benyamin Grosman, Alicia Jenkins iD, Hannah Jones, Natalie Kurtz, Melissa H Lee iD, Richard MacIsaac iD, Emma Netzer, Barbora Paldus iD und 6 weitere

Diabetes Care · 2024

DOI: 10.2337/dc23-2217 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Cheng Yi Yuan und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Melbourne Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Medtronic Diabetes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To determine feasibility and compare acceptance of an investigational Medtronic enhanced advanced hybrid closed-loop (e-AHCL) system in adults with type 1 diabetes with earlier iterations. RESEARCH DESIGN AND METHODS This nonrandomized three-stage (12 weeks each) exploratory study compared e-AHCL (Bluetooth-enabled MiniMed 780G insulin pump with automatic data upload [780G] incorporating an updated algorithm; calibration-free all-in-one disposable sensor; 7-day infusion set) preceded by a run-in (non-Bluetooth 780G [670G V4.0 insulin pump] requiring manual data upload; Guardian Sensor 3 [GS3] requiring calibration; 3-day infusion set), stage 1 (780G; GS3; 3-day infusion set), and stage 2 (780G; calibration-free Guardian Sensor 4; 3-day infusion set). Treatment satisfaction was assessed by Diabetes Technology Questionnaire (DTQ)-current (primary outcome) and other validated treatment satisfaction tools with glucose outcomes by continuous glucose monitoring metrics. RESULTS Twenty-one of 22 (11 women) participants (baseline HbA1c 6.7%/50 mmol/mol) completed the study. DTQ-current scores favored e-AHCL (123.1 [17.8]) versus run-in (101.6 [24.2]) and versus stage 1 (110.6 [20.8]) (both P < 0.001) but did not differ from stage 2 (119.4 [16.0]; P = 0.271). Diabetes Medication System Rating Questionnaire short-form scores for “Convenience and Efficacy” favored e-AHCL over run-in and all stages. Percent time in range 70–180 mg/dL was greater with e-AHCL versus run-in and stage 2 (+2.9% and +3.6%, respectively; both P < 0.001). Percent times of <70 mg/dL for e-AHCL were significantly lower than run-in, stage 1, and stage 2 (−0.9%, −0.6%, and −0.5%, respectively; all P < 0.01). CONCLUSIONS e-AHCL was feasible. User satisfaction increased compared with earlier Medtronic HCL iterations without compromising glucose control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1InsulinsAdultHumansFemaleBlood GlucoseBlood Glucose Self-MonitoringAlgorithmsInsulin Infusion SystemsInsulinHypoglycemic Agents

Substanzen

Blood GlucoseInsulinsInsulinHypoglycemic Agents

Autor:innen und Institutionen

  • University of Melbourne Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Department of Endocrinology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Medtronic, Northridge, CA.
  • The Baker Institute, Prahran, Victoria, Australia.
  • The Australian Centre for Accelerating Diabetes Innovations, Melbourne, Victoria, Australia.
  • Cairnmiller Institute, Hawthorn East, Victoria, Australia.

ORCID-Profile: Alicia Jenkins, Melissa H Lee, Richard MacIsaac, Barbora Paldus, Steven Trawley, David N O'Neal

Förderung

  • Medtronic Diabetes

Zitieren

APA

Yuan, C. Y., Kong, Y. W., Amoore, T., Brown, K., Grosman, B., Jenkins, A., Jones, H., Kurtz, N., Lee, M. H., MacIsaac, R., Netzer, E., Paldus, B., Robinson, L., Roy, A., Sims, C. M., Trawley, S., Vogrin, S., & O'Neal, D. N. (2024). Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System. Diabetes Care. https://doi.org/10.2337/dc23-2217

Vancouver

Yuan CY, Kong YW, Amoore T, Brown K, Grosman B, Jenkins A, et al. Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System. Diabetes Care. 2024. doi:10.2337/dc23-2217

BibTeX
@article{Yuan2024,
  author = {Yuan, Cheng Yi and Kong, Yee W and Amoore, Tess and Brown, Katrin and Grosman, Benyamin and Jenkins, Alicia and Jones, Hannah and Kurtz, Natalie and Lee, Melissa H and MacIsaac, Richard and Netzer, Emma and Paldus, Barbora and Robinson, Lesley and Roy, Anirban and Sims, Catriona M and Trawley, Steven and Vogrin, Sara and O'Neal, David N},
  title = {Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-2217}
}
Kostenlos starten →